Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical rebate agreement for Formoterol/Aclidiniumbromide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Aclidiniumbromid (ATC-Code nach WHO: R03AL05)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum purchase volume; quantities depend on patient numbers, prescription behavior, and pharmacy stocki...

The buyer may end the Open-House procedure prematurely if exclusive agreements are concluded, which typically occurs 8-...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive rebate agreements according to §130a Abs. 8 SGB V for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05).
  • Open-House model: no individual negotiations, no exclusivity, continuous acceptance of participation requests.
Afficher le résumé complet

Non-exclusive pharmaceutical rebate agreement (Open-House model) for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05) under §130a Abs. 8 SGB V. The agreement is open to all qualified pharmaceutical companies throughout the participation period. No exclusivity, no guaranteed minimum volumes, and the contract ends by 30 June 2027 regardless of conclusion date. The buyer (AOK PLUS) reserves the right to terminate the procedure early if exclusive agreements are signed.

Risques

No guaranteed minimum purchase volume; quantities depend on patient numbers, prescription behavior, and pharmacy stocki...

The buyer may end the Open-House procedure prematurely if exclusive agreements are concluded, which typically occurs 8-...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered medicines.

Eligibility

  • Declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).

Administrative

  • Submission of participation documents via DTVP portal (access request required).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement for Formoterol/Aclidiniumbromide

Open-House model for concluding non-exclusive rebate agreements for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05). Any pharmaceutical company meeting participation conditions may join. No exclusivity, unknown purchase quantities, no minimum volume guarantee. Contract valid until 30 June 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2026 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
05 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
309969-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30